BRCA1 Gene Mutation: Cancer Risks, Testing, and Next Steps

BRCA1 stands for BReast CAncer gene 1. It is a tumor suppressor gene located on chromosome 17. The BRCA1 protein plays a critical role in repairing double-strand DNA breaks through a process called homologous recombination. When your cells divide, small errors can occur in the DNA. The BRCA1 protein helps fix those errors before they can lead to uncontrolled cell growth.

When someone inherits a mutation in their BRCA1 gene, this repair system does not work properly. Damaged DNA accumulates over time, which significantly raises the risk of developing certain cancers — most notably breast and ovarian cancer. BRCA1 mutations are inherited in an autosomal dominant pattern, meaning you only need one copy of the mutated gene (from one parent) for it to increase your cancer risk.

Approximately 1 in 400 to 1 in 500 people in the general population carry a BRCA1 mutation. The rate is significantly higher in certain populations: roughly 1 in 40 individuals of Ashkenazi Jewish descent carry a BRCA1 or BRCA2 founder mutation. While most BRCA1 mutations are inherited from a parent, a small number arise spontaneously (de novo), though this is rare.

BRCA1 is one of several genes in the DNA damage response network. Other genes involved in the same pathway include BRCA2, ATM, CHEK2, and PALB2. For a broader overview of when hereditary cancer testing is appropriate, see our guide on hereditary cancer screening.

BRCA1 is classified as a high-risk gene — the highest category of hereditary cancer risk alongside BRCA2. A BRCA1 mutation does not guarantee cancer, but the lifetime risk increases are substantial compared to the general population.

Breast cancer (women)

• General population lifetime risk: approximately 13%
• BRCA1 mutation carriers: approximately 50–72% lifetime risk
• BRCA1-associated breast cancers are more commonly triple-negative, which can influence treatment decisions
• Risk of contralateral breast cancer (a second breast cancer) is significantly elevated after a first diagnosis

Ovarian cancer

• General population lifetime risk: approximately 1–2%
• BRCA1 mutation carriers: approximately 44–46% lifetime risk
• This is one of the highest known hereditary ovarian cancer risks
• Risk-reducing salpingo-oophorectomy is typically recommended after childbearing is complete

Pancreatic cancer

• BRCA1 carriers have a modestly elevated risk, approximately 2–3× the general population rate
• The absolute lifetime risk remains relatively low (1–3%), but screening may be considered in families with a history of pancreatic cancer

Male breast cancer and prostate cancer

• Male BRCA1 carriers have a small but elevated breast cancer risk (approximately 1–2% lifetime risk)
• Some studies show a modest elevation in prostate cancer risk, particularly for aggressive forms

Key takeaway: Early detection saves lives. BRCA1 carriers who follow recommended screening and risk-reduction strategies significantly improve their outcomes. If you have a family history of breast or ovarian cancer, knowing your BRCA1 status allows you and your medical team to act early.

BRCA1 and BRCA2 are both high-risk hereditary cancer genes, but they have different risk profiles. Understanding the distinction helps guide screening and management decisions.

• Ovarian cancer risk: BRCA1 carries a higher ovarian cancer risk (approximately 44–46%) compared to BRCA2 (approximately 17–23%). This difference often influences the recommended timing of risk-reducing surgery.
• Breast cancer subtype: BRCA1 mutations are more commonly associated with triple-negative breast cancer, which does not respond to hormone therapy. BRCA2-associated breast cancers are more often hormone receptor–positive.
• Male breast cancer: BRCA2 carries a higher male breast cancer risk (approximately 6–8%) compared to BRCA1 (approximately 1–2%).
• Pancreatic cancer: Both genes carry modestly elevated pancreatic cancer risk, but BRCA2 is more strongly associated with pancreatic cancer than BRCA1.
• Prostate cancer: BRCA2 carriers have a more significantly elevated prostate cancer risk than BRCA1 carriers.
• Chromosome location: BRCA1 is located on chromosome 17; BRCA2 is on chromosome 13. Both are tumor suppressor genes involved in DNA repair, but they operate at different points in the homologous recombination pathway.

Both genes are included in standard multi-gene panel tests. If you have been tested for only one gene, or had older single-gene testing, you may want to discuss updated panel testing with your provider. For more details on how hereditary cancer testing works, see our complete guide to hereditary cancer genetic testing.

Because BRCA1 is a high-risk gene, NCCN recommends aggressive enhanced screening that begins earlier than standard population guidelines. Your provider may adjust these recommendations based on your personal and family history.

Women with a BRCA1 mutation

• Annual breast MRI starting at age 25–30
• Annual mammogram starting at age 30 (alternating with MRI every 6 months provides year-round surveillance)
• Clinical breast exam every 6–12 months
• Risk-reducing salpingo-oophorectomy (removal of ovaries and fallopian tubes) is typically recommended between ages 35 and 40, after childbearing is complete, due to the high ovarian cancer risk
• Discussion of risk-reducing mastectomy as an option to significantly lower breast cancer risk
• Chemoprevention options (tamoxifen, raloxifene) may be discussed based on individual circumstances

Men with a BRCA1 mutation

• Monthly breast self-examination starting at age 35
• Annual clinical breast exam starting at age 35
• Discuss prostate cancer screening (PSA testing) with your doctor starting at age 40

All BRCA1 carriers

• Cascade testing: first-degree relatives (parents, siblings, children) should be offered genetic testing, as each has a 50% chance of carrying the same mutation
• A licensed genetic counselor can help build a personalized screening plan based on your specific mutation, family history, and preferences
• Keep your entire healthcare team informed about your BRCA1 status so they can tailor your care appropriately

A positive BRCA1 result can feel overwhelming, but it is important to know that you have options. A positive result is not a diagnosis — it is information that empowers you and your medical team to take proactive steps. There are four main categories of evidence-based management.

1. Enhanced surveillance. This means more frequent and more sensitive screening than what is recommended for the general population. The goal is to detect cancer at the earliest, most treatable stage. For BRCA1 carriers, this includes breast MRI, mammogram, and clinical exams on a schedule determined by your age and risk profile.
2. Risk-reducing surgery. Prophylactic mastectomy reduces breast cancer risk by approximately 90–95%. Risk-reducing salpingo-oophorectomy reduces ovarian cancer risk by approximately 80% and also lowers breast cancer risk when performed before menopause. These are significant decisions with both benefits and trade-offs, and the timing depends on your age, family planning, and personal preferences.
3. Chemoprevention. Medications such as tamoxifen and raloxifene can reduce breast cancer risk in some carriers. These options are most relevant for carriers who choose enhanced surveillance over surgery. Your oncologist or breast specialist can discuss whether chemoprevention is appropriate for you.
4. Clinical trials. Researchers are actively studying new prevention and treatment strategies for BRCA1 carriers, including PARP inhibitors and immunotherapy approaches. Your genetic counselor or oncologist can help you find relevant clinical trials.

The right approach depends on your personal and family history, age, and individual preferences. For detailed guidance on navigating a positive result, see our resource on what to do after a positive genetic test result.

If you have received a positive BRCA1 genetic test result, here are the steps to take:

1. Share your results with your medical team. Your primary care physician, OB/GYN, or oncologist should know about your BRCA1 status immediately. This directly affects your screening plan, treatment decisions, and long-term care.
2. See a licensed genetic counselor. A genetic counselor can interpret your specific BRCA1 variant, review your personal and family history in detail, and create a personalized risk management plan. They can also help you understand the options outlined above and decide which approach is right for you.
3. Tell your first-degree relatives. BRCA1 mutations follow autosomal dominant inheritance. Each parent, sibling, and child has a 50% chance of carrying the same mutation. Cascade testing is the most effective way to identify which family members are at risk so they can begin appropriate screening early.
4. Begin NCCN-recommended screening immediately. Do not wait. Follow the enhanced screening guidelines for your age and sex, adjusted for your personal and family history. Early detection is the single most important factor in improving cancer outcomes for BRCA1 carriers.
5. Consider your management options carefully. Discuss risk-reducing surgery, chemoprevention, and clinical trial eligibility with a breast specialist or oncologist. These decisions do not need to be made immediately, but they should be part of an ongoing conversation with your care team.

For general guidance on interpreting different types of genetic test results, see our resource on understanding your genetic test results. If you have not been tested yet and want to find out whether hereditary cancer genetic testing is right for you, our free eligibility screener can help.

If a family member has already tested positive for a BRCA1 mutation, learn about what a family member's positive BRCA result means for you.

Ready to find out if you qualify for hereditary cancer testing? Learn more about BRCA testing eligibility and how to get started.

NCCN recommends BRCA1 genetic testing for individuals with a personal or family history of breast cancer diagnosed before age 50, ovarian cancer at any age, triple-negative breast cancer before age 60, male breast cancer, pancreatic cancer with Ashkenazi Jewish ancestry, or multiple breast cancer primaries. Testing is also recommended when a known BRCA1 mutation exists in the family.

Because BRCA1 follows autosomal dominant inheritance, each first-degree relative (parent, sibling, child) of a carrier has a 50% chance of also carrying the mutation. NCCN recommends offering genetic testing to all blood relatives once a BRCA1 mutation is identified in a family. Cascade testing is the most effective way to identify at-risk family members who can benefit from enhanced screening and risk-reduction strategies. Both male and female relatives should be tested, as men can carry and pass on the mutation.